Pfizer Inc. $PFE Shares Bought by Nissay Asset Management Corp Japan

Nissay Asset Management Corp Japan lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 795,895 shares of the biopharmaceutical company’s stock after buying an additional 26,632 shares during the period. Nissay Asset Management Corp Japan’s holdings in Pfizer were worth $19,165,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the business. Godfrey Financial Associates Inc. purchased a new position in Pfizer in the fourth quarter worth $26,000. Keb Asset Management LLC acquired a new stake in Pfizer in the second quarter valued at $26,000. Field & Main Bank purchased a new stake in shares of Pfizer during the 2nd quarter worth $27,000. HFM Investment Advisors LLC boosted its position in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares in the last quarter. Finally, Evolution Wealth Management Inc. grew its stake in shares of Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Down 0.2%

NYSE:PFE opened at $27.95 on Friday. Pfizer Inc. has a 52-week low of $23.58 and a 52-week high of $28.75. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The stock has a fifty day simple moving average of $25.55 and a 200-day simple moving average of $26.30. The company has a market capitalization of $159.31 billion, a PE ratio of 36.78 and a beta of 0.34.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the prior year, the company earned $0.78 EPS. The firm’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.2%. Pfizer’s dividend payout ratio is currently 226.32%.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Bank of America reduced their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. JPMorgan Chase & Co. lowered their target price on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 8th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a report on Monday, July 6th. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Finally, BMO Capital Markets decreased their price target on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.28.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COMIRNATY vaccine for adults 65 and older and people ages 5–64 with underlying conditions that increase the risk of severe COVID-19. Shipments to U.S. pharmacies, hospitals and clinics are beginning immediately, supporting seasonal vaccine revenue and confirming Pfizer’s continuing role in infectious-disease prevention. Reuters FDA approval article
• Positive Sentiment: Pfizer and Valneva’s Lyme disease vaccine candidate, PF-07307405, reached an additional regulatory milestone after its European Marketing Authorization Application was validated. If approved, the product could help diversify Pfizer’s vaccine portfolio beyond COVID-19. Pfizer COVID and Lyme vaccine milestones article
• Neutral Sentiment: Pfizer announced several clinical-development updates, including an early-stage autoimmune trial for PF-08154225, a Phase 1 study evaluating easier injection delivery for tilrekimig, a tucatinib continuation study and a post-marketing Xalkori study. These programs may strengthen the pipeline, but they remain too early or incremental to affect near-term valuation. Pfizer pipeline update
• Negative Sentiment: The updated COVID vaccine is aimed at older and high-risk patients, creating a substantially smaller addressable market than broad-based vaccination campaigns. That limits the likely revenue lift even though approval and immediate distribution are favorable developments. Pfizer updated COVID shot article
• Negative Sentiment: BioNTech’s failed colorectal-cancer vaccine trial pressured sentiment across the mRNA sector. Pfizer was relatively insulated because the setback involves BioNTech’s oncology program rather than a Pfizer-specific clinical failure, but the broader result reinforces investor concerns about the limits of mRNA technology outside infectious disease. BioNTech colorectal cancer trial article
• Negative Sentiment: Commentary continues to question Pfizer’s dividend sustainability because its payout ratio exceeds 100% and much of the turnaround case depends on cost reductions and growth targets that do not begin meaningfully until later in the decade. These concerns can cap enthusiasm despite Pfizer trading near its 52-week high.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.